Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Luye Pharma GroupFRA:LUP +1.74%51 Debt-to-Equity is 0.59 as of Dec. 2025, which is 22% below its 10-year median of 0.76. GuruFocus rates FRA:LUP with a GF Score™ of 51/100 and a GF Value™ of €0.36 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 812 Drug Manufacturers companies, Luye Pharma Group ranks worse than 74.38% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Luye Pharma Group's Debt-to-Equity or its related term are showing as below:
FRA:LUP'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.25 Med: 0.76 Max: 1.27
Current: 0.59
During the past 13 years, the highest Debt-to-Equity Ratio of Luye Pharma Group was 1.27. The lowest was 0.25. And the median was 0.76.
FRA:LUP's Debt-to-Equity is ranked worse than 74.38% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs FRA:LUP: 0.59
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Luye Pharma Group Debt-to-Equity Related Terms
Luye Pharma Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a Debt-to-Equity of 0.59 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Luye Pharma Group and its competitors. This is 22% below median its historical median of 0.76. Over the past decade, Luye Pharma Group's Debt-to-Equity has ranged from 0.25 to 1.27. According to the industry distribution chart, Luye Pharma Group ranks #604 out of 812 companies in the Drug Manufacturers industry, placing it in the top 74.4%.
Is Luye Pharma Group's Debt-to-Equity too high?
Luye Pharma Group's current Debt-to-Equity of 0.59 is 22% below median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 1.27. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Luye Pharma Group's value of 0.59 is 118.5% above this industry median. Based on the distribution chart, Luye Pharma Group ranks #604 out of 812 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Luye Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #604 out of 812 companies for Debt-to-Equity. This places Luye Pharma Group in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Luye Pharma Group's value of 0.59 is 118.5% above this benchmark. Historically, Luye Pharma Group's own Debt-to-Equity has ranged from 0.25 to 1.27 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 0.27, Luye Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current Debt-to-Equity of 0.59 is 118.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current Debt-to-Equity is 0.59, which is 22% below median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.36, compared to a current price of €0.23 — trading 35% below its estimated fair value. The current Debt-to-Equity is 0.59, which is 22% below median its 10-year median of 0.76 and 118.5% above the Drug Manufacturers industry median of 0.27. Luye Pharma Group's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Debt-to-Equity is 0.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.23 is trading 35% below its estimated GF Value™ of €0.36.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
Debt-to-Equity: 0.59 (22% below median its 10-year median of 0.76)
GF Value™: €0.36 vs. price of €0.23 (35% below fair value)
Industry Position: 118.5% above the Drug Manufacturers median (#604 of 812)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
51GF Score
Get the complete analysis for FRA:LUP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
